Abstract

Controlled delivery compositions and methods that enhance wound closure and reduce fibrotic scarring are described. The methods include treating a wound in a subject by administering to the subject a therapeutically effective amount of a first agent that promotes wound closure and a therapeutically effective amount of a second agent that inhibits scarring. The controlled delivery compositions include a therapeutically effective amount of a first agent that promotes wound closure and a therapeutically effective amount of a second agent that inhibits scarring. The controlled delivery compositions permit rapid release of the first agent and delayed release of the second agent.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

A method of modifying biomechanical properties of tissue in a region of interest includes application of laser energy to one or more first volumes of tissue in the region of interest to cause softening via photodegradation, and application of laser energy to one or more second volumes of tissue within the region of interest to cause stiffening via photocrosslinking. The one or more second volumes are different from the one or more first volumes.

IPC Classes  ?

• A61F 9/008 - Methods or devices for eye surgery using laser

Abstract

Methods of regenerating vital tooth tissue in situ after endodontic therapy include introducing a hydrogel scaffold into a root canal of a tooth in a patient after native pulp has been removed from the root canal. The hydrogel scaffold may comprise a sponge scaffold, and can be acellular. The hydrogel scaffold can contain chemotactic, angiogenic, neurogenic, and/or immunomodulatory biofactors that cause infiltration of endogenous cells from the patient into the root canal. Alternatively, such biofactors/drugs can be administered to the patient separately from the hydrogel scaffold. The hydrogel scaffold can fill the periapical space of an abscessed root.

IPC Classes  ?

• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/56 - Porous or cellular materials

Abstract

Described are methods of manufacturing engineered T cells and methods of using the engineered T cells to treat hematological malignancies. The engineered T cells can be administered in combination with allogeneic stem cell transplant and reduce the need for prophylactic immunosuppression.

IPC Classes  ?

• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/32 - T-cell receptors [TCR]
• A61K 40/41 - Vertebrate antigens
• A61K 40/50 - Cellular immunotherapy characterised by the use of allogeneic cells
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/86 - Viral vectors

Abstract

A composite mechanical metamaterial, comprising first and second electrically conductive components disposed relative to each other to act as opposite electrodes to induce contact electrification; wherein the first and second electrically conductive components, along with a dielectric component serving as a skeleton of the composite mechanical metamaterial, form a lattice of snapping curved semicircular-shaped segments, wherein each of the snapping curved semicircular-shaped segments has an elastic snap-through instability mechanism; and wherein the lattice comprises periodic repeatable parallel rows of the snapping curved semicircular-shaped segments.

IPC Classes  ?

• H02N 1/04 - Friction generators
• H01B 5/00 - Non-insulated conductors or conductive bodies characterised by their form

Abstract

A method of delivering cells to a target tissue is provided comprising depositing a hydrogel pre-gel comprising magnetic particle-loaded cells to the target tissue and, prior to or during gelation of the hydrogel, drawing the magnetic particle-loaded cells to the tissue with a magnetic field, followed by gelation of the hydrogel to lock the cells in place on the tissue. The cells may be mesenchymal stem cells, such as adipose-derived mesenchymal stem cells, and the target tissue may be adventitial tissue of an aneurysm in a blood vessel. Also provided are devices useful in the method.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61M 25/09 - Guide wires
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

The presently disclosed subject matter relates to a controlled release drug delivery system for cardiovascular applications. Specifically, the discloses subject matter involves utilizing injectable hydrogels coupled with degradable microparticles, formulated into compositions to provide a sustained release of therapeutic agents. The present disclosure further includes the application of these composition for use in methods of treating cardiovascular conditions.

IPC Classes  ?

• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/14 - Particulate form, e.g. powders

Abstract

The invention relates to a thermal balloon catheter that includes a catheter, one or more balloons, and optionally a flexible, biodegradable endovascular medical implant device, e.g., a biocarpet device. The thermal balloon catheter is effective for deployment of the biocarpet device, or performing thermal angioplasty (in the absence of the biocarpet device). In one embodiment of the invention, a method of deploying a flexible, biodegradable endovascular medical implant device, e.g., biocarpet device, in a target vascular region includes forming a thermoformed structure, e.g., tube or cylinder, that can conform to the geometry or anatomy of the target vascular region.

IPC Classes  ?

• A61B 18/04 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
• A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
• A61B 18/14 - Probes or electrodes therefor
• B32B 1/08 - Tubular products

Abstract

Methods are disclosed herein for producing a mammalian acoustic extracellular matrix (ECM) hydrogel. In further embodiments, mammalian acoustic ECM hydrogels are disclosed that are produced using the disclosed methods. Also disclosed is a mammalian acoustic ECM hydrogel, wherein the hydrogel is thermoreversible. Methods of using these acoustic ECM hydrogels are also disclosed.

IPC Classes  ?

• A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/52 - Hydrogels or hydrocolloids

Goods & Services

Publication of books, magazines, periodicals featuring clinical trial results; publication of books, magazines, periodicals featuring results of surveys and studies in the field of health; Providing educational training in the field of medicine; Education services, namely, providing classes and instruction in the field of medicine; organizing and conducting of educational conferences, colloquiums, seminars and symposiums in the field of medicine; Providing online non-downloadable electronic publications in the nature of brochures in the field of organ health Medical research; Provision of information in connection with medical and scientific research in the field of pharmaceutical products and clinical trials; medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information about the results of clinical trial and medical studies Medical analyses for the diagnosis and treatment of individuals with a disease and its subcategories; conducting medical studies in the field of organ disease for the purposes of medical diagnosis or treatment; health counseling services; preparation of medical reports for medical diagnostic or treatment purposes using data from medical diagnostics testing, monitoring, and reporting services and risk assessment studies; provision of news and information in the field of medicine; providing information via the Internet in the field of health; providing medical information to patients and medical professionals in the form of reports in the field of organ disease and treatment; medical diagnoses of organ disease, and medical consultancy services related thereto; providing medical information to patients and medical professionals in the form of reports in the field of organ disease

Abstract

A method for identifying, quantifying, and phenotyping vascular calcification (VC) in patients includes accessing a set of medical scan images of a vascular tissue sample extracted from the one or more patients, and further inputting the set of medical scan images into one or more machine-learning models trained to segment the set of medical scan images to identify a tissue region, a lipid pool region, and a set of vascular calcifications detectable from the set of medical scan images. The method further includes determining, based on the segmented set of medical scan images, one or more feature characteristics corresponding to each of the identified set of vascular calcifications, and identifying each of the identified set of vascular calcifications as corresponding to one or more of a plurality of vascular calcification phenotypes based at least in part on the one or more feature characteristics and the identified lipid pool region.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation
• G06N 20/00 - Machine learning
• G06N 3/08 - Learning methods
• G06T 5/00 - Image enhancement or restoration
• G06T 3/00 - Geometric image transformations in the plane of the image

Abstract

Compositions are disclosed herein that include an extracellular matrix (ECM) hydrogel and matrix bound nanovesicles (MBV). These compositions provide a synergistic effect and are of use for treating subjects.

IPC Classes  ?

• A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61K 9/50 - Microcapsules
• A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

Provided herein is a bioreactor system, including a cell growth platform having a hydrogel arranged thereon, at least one first cell received on and/or in the hydrogel, a flow channel configured to receive a flow of a liquid therethrough, a separator arranged between the cell growth platform and the flow channel and having a first surface that faces the cell growth platform and a second surface in fluid communication with the flow channel, and at least one second cell received on the separator.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• A61L 27/52 - Hydrogels or hydrocolloids
• A61K 35/44 - VesselsVascular smooth muscle cellsEndothelial cellsEndothelial progenitor cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

This document relates to AAV vectors (e.g., AAV2 vectors). For example, AAV vectors (e.g., AAV2 vectors) containing an AAV capsid polypeptide that includes an amino acid sequence set forth in Table 1 (or a variant thereof) or Formula A, such AAV capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV capsid polypeptides, host cells containing and/or expressing such nucleic acid molecules, and methods and materials for making or using such vectors and/or AAV capsid polypeptides are provided.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/86 - Viral vectors

Abstract

The invention relates to a novel two-electrode approach that obviates non-specific adsorption (NSA) commonly termed, “biofouling” on biosensors. The unique two-electrode approach is based on baseline and sensing electrodes that are exposed to conditions with and without the detecting analyte. Proper corrections for normalization of the baseline and the intercept are made to eliminate the prevalence of biofouling and accurately detect the presence of the biomarkers without any interference. A corrective method nullifies the influence of any interfering factors present in animal and human blood, serum, biological body fluids or in any natural or synthetic solution that could bind to the label free biosensor (i.e., non-specific adsorption) and influence its sensitivity, accuracy, rapid detectability, specificity, precision, and reproducibility.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to Chevrel-phase materials and methods of preparing these materials utilizing a precursor approach. The Chevrel-phase materials are useful in assembling electrodes, e.g., cathodes, for use in electrochemical cells, such as rechargeable batteries. The Chevrel-phase materials have a general formula of Mo6Z8 (Z=sulfur) or Mo6Z18-yZ2y (Z1=sulfur; Z2=selenium), and partially cuprated Cu1Mo6Z8 as well as partially de-cuprated Cu1-xMgxMo6S8 and the precursors have a general formula of MxMo6Z8 or MxMo6Z18-yZ2y, M=Cu. The cathode containing the Chevrel-phase material in accordance with the invention can be combined with a magnesium-containing anode and an electrolyte.

IPC Classes  ?

• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
• C01B 19/00 - SeleniumTelluriumCompounds thereof
• C01G 39/00 - Compounds of molybdenum
• C01G 39/06 - Sulfides
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 10/052 - Li-accumulators

Abstract

This document relates to AAV vectors (e.g., AAV2 vectors). For example, AAV vectors (e.g., AAV2 vectors) containing an AAV capsid polypeptide that includes an amino acid sequence set forth in Table 1 (or a variant thereof) or Formula A, such AAV capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV capsid polypeptides, host cells containing and/or expressing such nucleic acid molecules, and methods and materials for making or using such vectors and/or AAV capsid polypeptides are provided.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/86 - Viral vectors

Abstract

A device for containment of an organ ex vivo and confluent distribution of an ultrasound field to the organ during ex vivo machine perfusion may include a container, a plurality of ultrasound transducers mounted to the container, and a power generator in operable communication with each of the ultrasound transducers. The container may define a reservoir and a plurality of apertures extending through a wall of the container and in communication with the reservoir, with the reservoir being configured for receiving the organ therein. Each of the ultrasound transducers may extend through a respective aperture of the plurality of apertures and may be configured for delivering ultrasound energy into the reservoir and to a respective portion of the organ therein. The power generator may be configured for selectively powering the ultrasound transducers to deliver ultrasound energy.

IPC Classes  ?

• A01N 1/168 - Physical preservation processes using electromagnetic fields or radiationPhysical preservation processes using acoustic waves or corpuscular radiation
• A01N 1/122 - Preservation or perfusion media
• A01N 1/143 - Apparatus for organ perfusion

Abstract

Embodiments disclosed include systems, methods, and apparatuses, directed to administering thermal neural modulation to mammalian tissue to control nerve conduction. Embodiments disclosed include an apparatus comprising a thermal energy source, a first heat exchanger coupled to the thermal energy source and configured to receive thermal energy therefrom, a thermal applicator configured to be disposed and secured to the anatomy of a subject having a nerve therein, in contact with the skin on the anatomy and overlying a treatment portion of the nerve, the thermal applicator configured to transfer thermal energy to the skin to raise the temperature of the treatment portion of the nerve above a physiologic temperature, a second heat exchanger is coupled to the thermal applicator and configured to transfer thermal energy thereto, and a fluid conduit having a first portion coupled to the first heat exchanger and a second portion coupled to the second heat exchanger. The fluid conduit is configured to have fluid circulated therethrough to convey thermal energy from the thermal energy source via the first heat exchanger and to the thermal applicator via the second energy at a temperature.

IPC Classes  ?

• A61F 7/00 - Heating or cooling appliances for medical or therapeutic treatment of the human body
• A61N 1/40 - Applying electric fields by inductive or capacitive coupling
• A61N 5/02 - Radiation therapy using microwaves
• A61N 5/06 - Radiation therapy using light

Abstract

Provided herein are compositions including a binding reagent for a Zika virus (ZIKV) epitope, pharmaceutical compositions including such binding reagents, and methods of detecting ZIKV binding antibodies and ZIKV neutralizing antibodies in patients.

IPC Classes  ?

• C07D 491/113 - Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61P 31/14 - Antivirals for RNA viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

An intravaginal device configured to be deployed within a vaginal tract of a patient for treating, reducing risks associated with, and/or preventing sexually transmitted infection includes a body having a flexible biocompatible material. The intravaginal device also includes: a flexible sensor array embedded in the body having at least one of a sodium sensor or pH sensor; a reservoir embedded in the body including a therapeutic agent configured to be released by an electro-responsive electrode assembly; and a near field communication circuit configured for wireless communication with an external device for wireless charging, data transmission, and receipt of control signals. The intravaginal device also includes a device controller configured to activate the electro-responsive electrode assembly to release the therapeutic agent from the reservoir in response to signals detected by the flexible sensor array and/or control signals received from the external device via the near field communication circuit.

IPC Classes  ?

• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• A61B 5/282 - Holders for multiple electrodes
• C08L 83/04 - Polysiloxanes

Abstract

A system includes a device including a handle and a sampling enclosure connected to the handle. The sampling enclosure includes an opening to place an internal volume of the sampling enclosure in fluid connection with tissue, a first port in fluid connection with the internal volume to deliver fluid under pressure to tissue via the opening, and a second port in fluid connection with the internal volume to draw a sample into the internal volume. The system further includes a source of the fluid, a pressurizing mechanism in connection with the source of fluid and with the first port, and a source of negative pressure in connection with the second port. A sample collection volume is placed in fluid connection with the source of negative pressure and with the second port.

IPC Classes  ?

• A61B 10/02 - Instruments for taking cell samples or for biopsy
• A61B 5/15 - Devices for taking samples of blood
• A61M 3/02 - EnemataIrrigators

Abstract

Methods are provided for preparing and treating graft tissue, such as a solid organ, for example a lung, comprising contacting the graft tissue with protective amounts of a heparanase inhibitor prior to and/or after transplantation of the graft tissue. Graft tissue, such as lung tissue prepared by the method also are provided. Methods are provided for transplanting graft tissue, such as a solid organ, for example a lung, comprising contacting the graft tissue with protective amounts of a heparanase inhibitor prior to and/or after transplantation of the graft tissue.

IPC Classes  ?

• A01N 1/126 - Physiologically active agents, e.g. antioxidants or nutrients
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12N 9/99 - Enzyme inactivation by chemical treatment

Abstract

An optical fiber-based monitoring system and associated method includes a light source structured and configured for generating a first light signal, one or more multimode interferometric fiber structures, such as an SMS or SMSMS fiber structure, structured and configured to receive the first light signal and output an output light signal indicative of a parameter associated with the multimode interferometric fiber structure, and a photodetector coupled to an output of multimode interferometric fiber structure for converting the output light signal into an electrical signal.

IPC Classes  ?

• G01D 5/353 - Mechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable using optical means, i.e. using infrared, visible or ultraviolet light with attenuation or whole or partial obturation of beams of light the beams of light being detected by photocells influencing the transmission properties of an optical fibre
• G01H 9/00 - Measuring mechanical vibrations or ultrasonic, sonic or infrasonic waves by using radiation-sensitive means, e.g. optical means
• G01K 11/32 - Measuring temperature based on physical or chemical changes not covered by group , , , or using changes in transmittance, scattering or luminescence in optical fibres
• G01R 33/032 - Measuring direction or magnitude of magnetic fields or magnetic flux using magneto-optic devices, e.g. Faraday

Abstract

This disclosure relates to using Mu Opioid Receptor (MOR) antagonists.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

Efficient simulation of a quantum computer can be achieved by minimizing the time required for data exchange between a host processor and a specialized processor simulating quantum computations. The data exchange time can be minimized using a partitioned memory that facilitates the exchange from the host processor to the specialized processor of the data to be processed simultaneously with the exchange from the specialized processor to the host processor of the data already processed. The data exchange time can also be minimized by identifying data that would not change as a result of a quantum computation, and by not exchanging such data.

IPC Classes  ?

• G06N 10/80 - Quantum programming, e.g. interfaces, languages or software-development kits for creating or handling programs capable of running on quantum computersPlatforms for simulating or accessing quantum computers, e.g. cloud-based quantum computing

Abstract

The present invention relates to methods and compositions for transplanting non-lymphoid tissues into lymphoid organs. It may be used to cultivate organ tissues including for the purpose of supplementing or reconstituting organ function. Tissues that may be propagated in this manner include but are not limited to lung, kidney, thyroid, intestine, and brain.

IPC Classes  ?

• A61K 35/26 - LymphLymph nodesThymusSpleenSplenocytesThymocytes
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
• A61K 35/39 - PancreasIslets of Langerhans
• A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells
• A61K 35/55 - Glands not provided for in groups , e.g. thyroids, parathyroids or pineal glands

Abstract

The present disclosure relates to a method of determining whether a subject is at risk of prostate cancer recurrence based on the detection of fusion genes.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 40/20 - Supervised data analysis
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

A method (and system) of segmenting one or more histological structures in a tissue image represented by multi-parameter cellular and sub-cellular imaging data includes receiving coarsest level image data for the tissue image, wherein the coarsest level image data corresponds to a coarsest level of a multiscale representation of first data corresponding to the multi-parameter cellular and sub-cellular imaging data. The method further includes breaking the coarsest level image data into a plurality of non-overlapping superpixels, assigning each superpixel a probability of belonging to the one or more histological structures using a number of pre-trained machine learning algorithms to create a probability map, extracting an estimate of a boundary for the one or more histological structures by applying a contour algorithm to the probability map, and using the estimate of the boundary to generate a refined boundary for the one or more histological structures.

IPC Classes  ?

• G06T 7/143 - SegmentationEdge detection involving probabilistic approaches, e.g. Markov random field [MRF] modelling
• G06T 7/00 - Image analysis
• G06T 7/12 - Edge-based segmentation
• G06T 7/149 - SegmentationEdge detection involving deformable models, e.g. active contour models
• G06V 10/52 - Scale-space analysis, e.g. wavelet analysis
• G06V 10/70 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

Abstract

Described is a device that can include a waveguide. The waveguide can include a first segment and a second segment. The device can include a plurality of rings disposed between the first segment and the second segment. The plurality of rings can include a magneto-optic material. The magneto-optic material can exhibit a non-reciprocal phase shift. The device can include an analyzer configured to receive first light from the first segment and second light from the second segment.

IPC Classes  ?

• G02F 1/095 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on magneto-optical elements, e.g. exhibiting Faraday effect in an optical waveguide structure
• G02B 6/27 - Optical coupling means with polarisation selective and adjusting means

Abstract

A method of predicting cancer recurrence risk for an individual includes receiving patient spatial multi-parameter cellular and sub-cellular imaging data for a tumor of the individual, and analyzing the patient spatial multi-parameter cellular and sub-cellular imaging data using a prognostic model for predicting cancer recurrence risk to determine a predicted cancer recurrence risk for the individual, wherein the joint prognostic model is based on spatial correlation statistics among features derived for a plurality of intra-tumor spatial domains from spatial multi-parameter cellular and sub-cellular imaging data obtained from a plurality of cancer patients.

IPC Classes  ?

• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G06F 18/21 - Design or setup of recognition systems or techniquesExtraction of features in feature spaceBlind source separation
• G06F 18/211 - Selection of the most significant subset of features
• G06N 20/00 - Machine learning
• G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
• G06V 10/50 - Extraction of image or video features by performing operations within image blocksExtraction of image or video features by using histograms, e.g. histogram of oriented gradients [HoG]Extraction of image or video features by summing image-intensity valuesProjection analysis
• G06V 10/771 - Feature selection, e.g. selecting representative features from a multi-dimensional feature space
• G06V 10/776 - ValidationPerformance evaluation
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Methods and systems for automated neurocognitive training to extend relief of treatment-resistant mental disorders are described herein. An example method includes administering a drug having an antidepressant effect to a patient, and administering a neurocognitive training protocol to the patient during a critical time period following administration of the drug. Additionally, the step of administering the neurocognitive training protocol to the patient includes delivering, using a computing device, a plurality of automated neurocognitive training sessions to the patient. A plurality of conditioning sequences are presented to the patient during delivery of each of the automated neurocognitive training sessions, where each respective conditioning sequence includes a respective non-self-relevant stimulus and a respective self-relevant stimulus.

IPC Classes  ?

• A61M 21/00 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 25/24 - Antidepressants

Abstract

A method of treating osteoarthritis includes an injector system comprising an agent to increase estrogen receptor-alpha in affected cartilage wherein the agent is delivered locally to the affected cartilage. The agent to increase estrogen receptor-alpha comprises at least one of an agent to effect knock-in of an estrogen receptor-alpha gene, an agent to effect interference with microRNA which suppress estrogen receptor-alpha gene expression, or an agent to effect enhancement of estrogen receptor-alpha gene expression.

IPC Classes  ?

• C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Provided herein are methods and compositions for treating a heart disease in a subject. The methods comprise administering a therapeutically effective amount of a vector encoding a polynucleotide encoding a protein kinase G1 (PKG1) to the subject and the compositions comprise a polynucleotide encoding a protein kinase G1 (PKG1).

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C12N 15/864 - Parvoviral vectors
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Goods & Services

Downloadable computer software for analyzing genetic data; recorded computer software for analyzing genetic data; computer software platforms, recorded and downloadable, for providing reports and health plans in the field of genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics, interactomics and multiomic testing, which integrate machine learning and artificial intelligence systems; downloadable computer application software for mobile phones, namely, software for providing reports and health plans for testing in the field of genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics, interactomics and multiomics; downloadable databases in the field of genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics, interactomics and multiomics, which integrate machine learning and artificial intelligence systems; electronic databases in the field of genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics, interactomics and multiomics recorded on computer media; downloadable interactive databases in the field of genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics, interactomics and multiomics; electronic interactive databases in the field of genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics, interactomics and multiomics recorded on computer media; downloadable data processing software; recorded data processing software Medical research services; laboratory research in the field of genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics, interactomics and multiomics; medical and scientific laboratory services; laboratory analysis in the field of genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics and multiomics; scientific analysis in the field of genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics, interactomics and multiomics; biological and biochemical analysis; technical data analysis in the field of genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics, interactomics and multiomics; computer services for the analysis of data, namely, data automation and collection service using proprietary software to analyze service data, which integrate machine learning and artificial intelligence systems; data storage, namely, online electronic data storage; laboratory analysis of samples taken from persons in the field of genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics, interactomics and multiomics; providing online interactive computer databases in the field of science, namely, genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics, interactomics and multiomics; computer services for the analysis of data, namely, analysis of scientific genetic data in the field of genomics, epigenomics, metabolomics, microbiomics, proteomics, transcriptomics, lipidomics, glycomics, cellomics, interactomics and multiomics, which integrate machine learning and artificial intelligence systems Human healthcare services; medical testing for diagnostic or treatment purposes in the field of age-related and/or chronic diseases or conditions; genetic testing for medical and healthcare purposes; medical analysis of samples taken from persons for diagnostic and treatment purposes provided by medical laboratories; medical advisory services; medical analysis services for the diagnosis of age-related and/or chronic diseases or conditions; medical treatment of age-related and/or chronic diseases or conditions; medical counselling services; health clinic services in the nature of medical clinics; dietary guidance; health counselling; health screening services in the field of age-related and/or chronic diseases or conditions; healthcare services; beauty consultancy; human hygienic and beauty care; consultation in the field of health and wellness; information services relating to health and wellness; advisory services in relation to health and wellness; analyzing data in computer databases for purposes of health and wellness; consultancy relating to health and wellness; providing a website featuring information in the field of health and wellness

Abstract

An adjustable mounting system for selectively coupling an external device or arrangement to a physical structure includes a mounting track positioned along a longitudinal axis for coupling to the physical structure. The mounting track includes a number of rails extending a distance along the longitudinal axis for having the external device or arrangement adjustably coupled thereto at any location along the distance. The system further includes a number of decorative covers selectively coupled to the mounting track.

IPC Classes  ?

• E04F 11/18 - BalustradesHandrails

Abstract

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to an ENPP1 polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to an ENPP1 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer (e.g., one or more sarcomas) are provided.

IPC Classes  ?

• A61K 40/42 - Cancer antigens
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes

Abstract

Provided is a method of preparing a donor pancreas tissue for transplantation comprising sourcing a pancreas tissue that is suitable for transplantation and infusing the pancreas tissue with an effective amount of a composition comprising ethanol and/or acetic acid plus a contrast agent to ablate, and track ablation of, an exocrine portion of the pancreas tissue. Also provided is a method of transplantation comprising obtaining a donor pancreas tissue having normal levels of endocrine function and low levels of exocrine function and implanting the donor pancreas tissue into a recipient. The mixed composition may also be used to treat the pancreas of a patient.

IPC Classes  ?

• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 35/39 - PancreasIslets of Langerhans
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

Provided herein is a computer-implemented method including receiving, with at least one processor, training data, the training data comprising genomic data and diagnostic data from a plurality of patients, determining, with at least one processor and based at least on the genomic data and the diagnostic data, an association between the genomic data and the diagnosis data, training, with at least one processor and based on the association, a machine learning model, a machine learning model configured to generate an output, the output comprising a prediction of a patient diagnosis.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G16B 40/20 - Supervised data analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06N 20/10 - Machine learning using kernel methods, e.g. support vector machines [SVM]

Abstract

The present disclosed subject matter relates to assays, methods, and kits for determining protein-nucleic acid association and dissociation kinetics.

IPC Classes  ?

• G01N 33/557 - ImmunoassayBiospecific binding assayMaterials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present disclosure provides compounds and methods for treating cancer, such as prostate cancer responsive to inhibition and/or degradation of androgen receptor ("AR") polypeptide, and/or breast cancer responsive to inhibition and/or degradation of estrogen receptor ("ER") polypeptide and/or AR polypeptide.

IPC Classes  ?

• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• C07D 215/12 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
• C07D 215/14 - Radicals substituted by oxygen atoms
• C07D 241/40 - Benzopyrazines
• C07D 307/34 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
• A61P 35/00 - Antineoplastic agents

Abstract

OF THE INVENTION Provided herein is a method of preparing an extracellular matrix (ECM) material, including incubating vaginal tissue in a protease, incubating the vaginal tissue in a solution including at least one detergent, incubating the vaginal tissue in a composition including at least one disinfecting agent, thereby producing a decellularized ECM material, lyophilizing the decellularized ECM material, thereby producing a lyophilized ECM material, comminuting the lyophilized ECM material, partially or completely solubilizing the comminuted, lyophilized ECM material with an acid protease to produce solubilized ECM, lyophilizing the solubilized ECM to produce lyophilized, solubilized ECM.

IPC Classes  ?

• A61K 35/48 - Reproductive organs
• A61K 9/06 - OintmentsBases therefor
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof

Abstract

A surgical drill system for use with a drill bit includes a base and a drill head positioned forward of the base which is operatively connected to the base. The drill head includes a drill bit interface to which a shaft of the drill bit is attachable so that an axis of the shaft of the drill extends at an angle to an orientation of the drill head at the position of the drill bit interface. The surgical drill system further includes a drive system in operative connection with the drill bit interface which is configured to rotate the drill bit about the axis of the shaft of the drill bit when connected to the interface.

IPC Classes  ?

• A61B 17/16 - Instruments for performing osteoclasisDrills or chisels for bonesTrepans
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

A system for prescribing insulin doses is provided, wherein a first titration application component structured to is implemented on a patient computing device of the patient, wherein the first titration application component logs glucose level data measured from the patient and insulin dose data indicative of a number of insulin doses given to the patient. The system includes a provider computing including a second titration application component, wherein the second titration application component is structured and configured to receive the glucose level data and the insulin dose data from the patient computing device, determine a correction factor based on a sensitivity constant specified by the healthcare provider, and determine the insulin dose recommendation for the patient based on the insulin dose data, the glucose level data and the correction factor, wherein the provider computing device is structured and configured to transmit the insulin dose recommendation to the patient computing device.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation

Abstract

Topical compositions including β-alanine and a transient receptor potential cation channel subfamily M (melastatin) member 8 (TRPM8) agonist, such as menthol, are disclosed. Also disclosed are methods of decreasing skin inflammation or redness in a subject, and methods of decreasing frequency or duration of symptoms of inflammatory skin conditions, such as rosacea.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 8/34 - Alcohols
• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 17/04 - Antipruritics
• A61Q 5/02 - Preparations for cleaning the hair
• A61Q 19/10 - Washing or bathing preparations

Abstract

Provided are compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, or Formula IX, or their pharmaceutically acceptable salts for increasing intracellular NAD levels.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/33 - Heterocyclic compounds

Abstract

The invention relates to shape-specific cerium oxide nanoparticles (CNPs). methods of preparing CNPs. and methods of using CNPs to treat and/or inhibit and/or reduce and/or reverse the complications of respiratory syncytial virus (RSV) disease and other infections that cause pathologic immune responses. through the balance of favorable immunomodulation and reduced lung immunopathology. CNPs have the capability to switch between Ce3+ and Ce4+ oxidation states (e.g., to scavenge reactive oxygen species). The shape-specific CNPs are synthesized into various shapes and sizes. These properties offer an opportunity to utilize CNPs to modulate macrophage phenotypes along the spectrum of M1 and M2 phenotypes to combat RSV infection and other infections that cause pathologic immune responses.

IPC Classes  ?

• A61K 33/24 - Heavy metalsCompounds thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/14 - Particulate form, e.g. powders
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Device, method, and system for cuffless blood pressure (BP) measurement are provided. The device, method, and system include the use of an oscillometric finger pressing method to determine blood pressure using smartphones or other readily available computing devices. Further devices, methods, and systems are provided to improve BP computation via modeling and/or the use of additional measurements of ECG and DC PPG.

IPC Classes  ?

• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/021 - Measuring pressure in heart or blood vessels
• A61B 5/0245 - Measuring pulse rate or heart rate using sensing means generating electric signals
• A61B 5/352 - Detecting R peaks, e.g. for synchronising diagnostic apparatusEstimating R-R interval

Abstract

Novel compounds and methods of using the compounds are provided herein. The compounds include novel carbon analogs of pyranose derivatives discovered to have Toll-like receptor 4 (Tlr4) inhibitory activity. The methods provide for treating infectious, inflammatory and post-traumatic disorders.

IPC Classes  ?

• C07H 3/02 - Monosaccharides
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• C07H 5/06 - Aminosugars

Abstract

The disclosed methods relate to forming microneedle arrays from a production mold that comprises a flexible mold material. The disclosed methods can be used to reproducibly manufacture undercut dissolvable and coated microneedle arrays with various shapes and structures.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• B29C 33/38 - Moulds or coresDetails thereof or accessories therefor characterised by the material or the manufacturing process
• B29C 33/40 - Plastics, e.g. foam or rubber
• B29C 33/50 - Moulds or coresDetails thereof or accessories therefor with means for, or specially constructed to facilitate, the removal of articles, e.g. of undercut articles with means for collapsing or disassembling elastic
• B29K 105/00 - Condition, form or state of moulded material
• B29L 31/00 - Other particular articles

Abstract

Disclosed cannula systems can detect the tissue type within which the cannula tip is located in real time using electrodes adjacent the cannula tip. The sensing cannula system can differentiate when the cannula tip is in adipose tissue or muscle based on electrical impedance. The system can be used in fat grafting and liposuction procedures, for example. An operator can detect if the cannula tip enters muscle by watching for an indicator light or audible alarm that is automatically activated by the device based on a change in sensed impedance. The device may also stop the flow of fat through a pump halting injection into the sub-muscular space.

IPC Classes  ?

• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems

Abstract

The present disclosure relates to methods and compositions for making a T cell with increased immune function comprising administering to said T cell a composition comprising a compound 991 and the uses thereof in increasing an immune response in a subject and/or treating a cancer in a subject.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 37/04 - Immunostimulants
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Abstract

The invention relates to a medical device that provides minimally invasive relief from stress and urge urinary incontinence, methods of making the medical device, apparatus and methods for testing the medical device, and treatment for urinary incontinence in a patient. The medical device includes a deformable intravesical urinary control medical device, including an implant device, that includes an outer membrane of a material selected from an impermeable material, a semi-permeable material, a self-sealing material, and combinations or blends thereof, an internal cavity formed of the outer membrane that includes one or more of an internal matrix including a material selected from low-density gas, fluid, gel, polymer or mixture thereof, an internal structure including a plurality of elastic or superelastic spindles, and a magnetic core positioned within the internal cavity; and an extracorporeal magnet that is positioned in the genital/perineal area of a patient body.

IPC Classes  ?

• A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
• A61M 27/00 - Drainage appliances for wounds, or the like

Abstract

The presently disclosed subject matter relates to antibodies and antigen-binding fragments that bind specifically to phosphorylated PDGFRA, and methods of treating cancer expressing MAN2A1-FER which ectopically phosphorylates PDGFRA. MAN2A1-FER can be expressed in liver cancer, prostate cancer, brain cancer, glioblastoma multiforme, breast cancer, lung cancer, non-small cell lung cancer, colon cancer, and renal cell carcinoma.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone). Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.

IPC Classes  ?

• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Methods for identifying tumor tissue and determining a margin of a tumor to be resected in a subject are disclosed within. The methods utilize guanidinoacetic acid (GAA) as a tissue biomarker of malignant brain tumors. The presently disclosed subject matter further relates to methods for providing a diagnosis or prognosis about a cancer in a subject.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 10/02 - Instruments for taking cell samples or for biopsy
• A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
• H01J 49/00 - Particle spectrometers or separator tubes
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to methods and compositions for transplanting non-lymphoid tissues into lymphoid organs. It may be used to cultivate organ tissues including for the purpose of supplementing or reconstituting organ function. Tissues that may be propagated in this manner include but are not limited to lung, kidney, thyroid, intestine, and brain.

IPC Classes  ?

• A61K 35/26 - LymphLymph nodesThymusSpleenSplenocytesThymocytes
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
• A61K 35/39 - PancreasIslets of Langerhans
• A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells
• A61K 35/55 - Glands not provided for in groups , e.g. thyroids, parathyroids or pineal glands

Abstract

A system for lung assist includes a fiber bundle section including a fiber bundle housing defining a fiber bundle compartment therein, and a fiber bundle within the fiber bundle compartment. The fiber bundle housing includes a first interface on a second end of the fiber bundle housing opposite a first end thereof. The system further includes a base section having a housing including a pressurizing section including a pressurizing compartment and an interface section. The interface section includes an extending section which extends from a lateral end of the pressurizing section. The interface section includes a second interface formed on the extending section, which includes a releasable seal member configured to form a releasable sealing connection with the first interface of the fiber bundle section. The base section housing and the fiber bundle housing are separate elements connected by a releasable, sealing connection between the first and second interfaces.

IPC Classes  ?

• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
• A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes
• A61M 60/113 - Extracorporeal pumps, i.e. the blood being pumped outside the patient’s body incorporated within extracorporeal blood circuits or systems in other functional devices, e.g. dialysers or heart-lung machines
• A61M 60/216 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller
• A61M 60/38 - Blood oxygenation
• A61M 60/825 - Contact bearings, e.g. ball-and-cup or pivot bearings

Abstract

A system for use in connection with a blood vessel includes a proximal section including a control system and a distal section. The distal section has connected thereto an application device configure to apply one or more ligating clips to the blood vessel to mechanically ligate the blood vessel. The application system is in connection with the control system. The distal section further has connected thereto a cutting device which is configured to mechanically cut tissue, including the blood vessel (for example, after compressive force is applied to the vessel via one or the one or more ligating clips).

IPC Classes  ?

• A61B 17/122 - Clamps or clips, e.g. for the umbilical cord
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/32 - Surgical cutting instruments
• A61B 17/3201 - Scissors
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

The present disclosure relates to a system and method for the production of a medical device for use as a nerve guide. The system and method provide for coating a polymer layer with particles, wherein the particles can comprise active agents for the repair or regeneration of nerve defects. The present invention further provides an implantable device for repairing or regenerating a nerve defect prepared by the system and method set forth above, and methods of treatment using said device.

IPC Classes  ?

• A61L 31/04 - Macromolecular materials
• A61L 31/10 - Macromolecular materials
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances

Abstract

ex vivoin vivoin vivo for research, diagnostic, or therapeutic purposes.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein are antimicrobial liquid crystal materials for use in therapeutic and wound-healing applications. Also provided herein are devices and methods for use of the antimicrobial liquid crystal materials, for example in artificial muscle, soft- engineering, and wound healing methods.

IPC Classes  ?

• C09K 19/38 - Polymers, e.g. polyamides
• C09K 19/54 - Additives having no specific mesophase

Abstract

Provided herein is a contrast agent composition comprising a contrast agent, such as a gadolinium chelate contrast agent, and a perfluorocarbon. Provided herein also is a method of imaging a patient's bladder or other organs containing a cavity, using MRI using a contrast agent composition comprising a contrast agent, such as a gadolinium chelate contrast agent, and a perfluorocarbon.

IPC Classes  ?

• A61K 49/10 - Organic compounds

Abstract

Disclosed are monoclonal antibodies and antigen binding fragments that specifically bind an antigen of epithelial ovaria carcinoma (EOC). Nucleic acid molecules encoding the heavy and light chain domains of the antibodies and the antigen binding fragments are also disclosed, as are host cells expressing the nucleic acid molecules. In addition, disclosed is the use of these monoclonal antibodies, antigen binding fragments, conjugates, nucleic acid molecules and vectors, such as for the treatment of EOC. Also disclosed are methods for detecting EOC and/or an antigen of EOC.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present disclosure relates to a method of determining effectiveness of corneal stromal stem cell therapy through evaluation of stem cell markers, inflammation markers, and assessing a scarring index.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/079 - Neural cells

Abstract

Embodiments described herein provide for a healthcare ecosystem of computing devices participating as nodes of a distributed ledger (e.g., blockchain). The distributed ledger includes NFTs representing corresponding patients, where the initial NET behaves logically as a token scaffold that represents a “digital twin” of the particular patient. The initial patient token represents personal profile data of patient personal data for the patient. The nodes may generate new data and/or new sub-tokens (or other blockchain entry type) representing new data, which the nodes associate with the token scaffold. The sub-tokens contain data for representing physical or digital specimens, health data, and data derived from the health data (e.g., cell lines, organoids, other model systems). As the nodes generate and associate new sub-tokens to the patient's token scaffold over time, the token scaffold graphs and facilitates integration of patient-specific data and evolves into a robust electronic health record (EHR) and digital twin.

IPC Classes  ?

• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules
• G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
• H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system

Abstract

Provided are compounds of Formula I or Formula II or their pharmaceutically acceptable salt, solvate, hydrate, formulation, tautomer, stereoisomer, or isotopologue for imaging tau aggregates. Compounds of Formula I or Formula II may be used for the detection of tau aggregates in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/415 - 1,2-Diazoles
• A61K 31/33 - Heterocyclic compounds

Abstract

Methods for treating a peripheral neuropathy are disclosed herein. Methods are also disclosed for improving nerve function in a subject with a peripheral neuropathy. These methods use a PNPase inhibitor or a PNPase purine nucleoside substrate. These methods include selecting the subject with the peripheral neuropathy; and administering to the subject a therapeutically effective amount of a purine nucleoside phosphorylase (PNPase) inhibitor and/or a PNPase purine nucleoside substrate.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

An insole for offloading injuries on an area of a plantar surface of a patient's foot includes a body having a shape corresponding to the plantar surface of the patient's foot including a top surface and a bottom surface; and at least one supportive, deformable, deflatable bubble chamber. The at least one bubble chamber extends from the top surface of the body. The at least one bubble chamber is configured to be deflated to relieve pressure on the plantar surface of the patient's foot. A kit including the insole and an article of footwear including a sole, an upper connected about a periphery of the sole defining an interior of the article of footwear, and the insole positioned in the interior of the article, are also provided.

IPC Classes  ?

• A43B 17/03 - Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined wedge-like or resilient filled with a gas, e.g. air
• A43B 7/142 - Footwear with health or hygienic arrangements with foot-supporting parts with pads or holes on one or more locations, or having an anatomical or curved form characterised by the location under the foot situated under the medial arch, i.e. under the navicular or cuneiform bones
• A43B 7/144 - Footwear with health or hygienic arrangements with foot-supporting parts with pads or holes on one or more locations, or having an anatomical or curved form characterised by the location under the foot situated under the heel, i.e. the calcaneus bone
• A43B 7/1445 - Footwear with health or hygienic arrangements with foot-supporting parts with pads or holes on one or more locations, or having an anatomical or curved form characterised by the location under the foot situated under the midfoot, i.e. the second, third or fourth metatarsal
• A43B 17/00 - Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined

Abstract

TOMTTOMT regulatory element, pharmaceutical compositions including the recombinant nucleic acids and vectors, and methods of use thereof.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/864 - Parvoviral vectors
• A61P 27/16 - Otologicals
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

Provided herein are composition and methods for repelling an arachnid or an insect from a subject or a fabric comprising applying a composition comprising one or more of hemoglobin, hemocyanin and myoglobin. Also provided are compositions comprising two or more of hemoglobin, hemocyanin and myoglobin.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 38/42 - HaemoglobinsMyoglobins
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Methods are disclosed for increasing retinal ganglion cell (RGC) survival and/or RGC axon regeneration and/or optic nerve survival and/or optic never regeneration in a subject in need thereof. These methods include locally administering to an eye of the subject a therapeutically effective amount of (a) isolated nanovesicles derived from an extracellular matrix and (b) a statin or a pharmaceutically acceptable salt thereof. Combination therapy is also disclosed for use in increasing RGC survival and/or RGC axon regeneration and/or or optic nerve survival and/or optic nerve regeneration in a subject. Disclosed is therapeutically effective amount of (a) isolated nanovesicles derived from an extracellular matrix and (b) a statin or a pharmaceutically acceptable salt thereof, for use in increasing RGC survival, RGC axon regeneration and/or optic nerve survival and/or optic never regeneration in a subject in need thereof in a subject, wherein the isolated nanovesicles and the statin are formulated for ophthalmic administration.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/51 - Nanocapsules
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

Presented herein are systems and methods of generating regions of interest (ROIs) in biomedical images of volume structures within a subject. One or more processors may identify a plurality of biomedical images of a volume stucture within a subject. The one or more processors may receive a plurality of tracings. The one or more processors may determine a plurality of curves to identify the ROI within the volume structure in accordance with a curve morphing function based at least on the plurality of tracings. The one or more processors may generate the ROI using the plurality of curves determined within the volume structure. The one or more processors may store, using one or more data structures, an association between the subject and the ROI.

IPC Classes  ?

• G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
• G06F 18/25 - Fusion techniques
• G06T 7/11 - Region-based segmentation
• G06T 7/12 - Edge-based segmentation
• G06T 7/155 - SegmentationEdge detection involving morphological operators
• G06T 7/136 - SegmentationEdge detection involving thresholding
• G06T 7/162 - SegmentationEdge detection involving graph-based methods
• G06T 7/187 - SegmentationEdge detection involving region growingSegmentationEdge detection involving region mergingSegmentationEdge detection involving connected component labelling

Abstract

An article of manufacture comprising a solid autologous serum ocular insert. In certain embodiments, the article further comprises a backing layer adjacent to the solid autologous serum ocular insert. The insert can be administered to an ocular surface of a subject for treating an ocular condition.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof

Abstract

A chimeric antigen receptor is disclosed that includes: (a) an extracellular high affinity streptavidin; (b) a hinge domain from CD8; (c) a CD28 transmembrane domain; (d) an intracellular 4-1BB and/or CD28 signaling domain; and (e) an intracellular CD3 zeta signaling domain, wherein (a)-(e) are in N-terminal to C-terminal order. Nucleic acids encoding this chimeric antigen receptor, and T and natural killer (NK) cells transformed with this chimeric antigen receptor are also disclosed. The use of this chimeric antigen receptor for the treatment of tumors is also disclosed.

IPC Classes  ?

• C07K 14/36 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from ActinomycesPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptomyces (G)
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

Systems and methods for calculating performance fatigability measures for subjects based on raw accelerometry data are described herein. An example method includes receiving raw accelerometry data, where the raw accelerometry data is collected from a subject during a walking task. The method further includes analyzing the raw accelerometry data to calculate a performance fatigability index for the subject based on the raw accelerometry data. Optionally, the subject is an aging human adult.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present disclosure provides adaptor molecules for use in adoptive cell therapies of Formula I, chimeric antigen receptor (CAR) systems based on the same, and methods of treatment using the same. Further provided are compounds of Formula II useful in preparing adaptor molecules, such as those of Formula III.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07K 14/725 - T-cell receptors

Abstract

A device for externally securing one or more extending elements which extend from external to a patient's body to internal to the patient's body includes a first member including one or more channels, wherein each of the one or more channels is dimensioned to position a length of one of the one or more extending elements at least partially therein, and one or more engagement members, and a second member including one or more cooperating engagement members configured to form a cooperating engagement with the one or more engagement members of the first member so that a surface of the second member is positioned adjacent to the one or more channels of the first member when the second member is engaged with the first member

IPC Classes  ?

• A61M 25/02 - Holding devices, e.g. on the body

Abstract

A wheelchair comprising a base assembly including a body portion having a frame and a plurality of wheel assemblies secured to the body portion. A seat assembly including a frame with a seating portion is supported on the base assembly, and a vertical lift assembly is secured to the base assembly and extends vertically upward therefrom. The vertical lift assembly is configured to move the seat assembly about and between a lowered vertical position and a raised vertical position. The lowered vertical position and the raised vertical position can be separated by at least 24.0 inches.

IPC Classes  ?

• A61G 5/10 - Parts, details or accessories
• A61G 5/04 - Chairs or personal conveyances specially adapted for patients or disabled persons, e.g. wheelchairs motor-driven

Abstract

A sensor system for detecting at least one analyte in an environment includes a dehumidifier system including at least one of a condenser unit and a desiccant unit and a sensor responsive to the analyte in fluid connection with the dehumidifier system.

IPC Classes  ?

• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• G01N 1/22 - Devices for withdrawing samples in the gaseous state
• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor

Abstract

The present disclosure relates to a method of identifying two or more characteristics of bacterium in a testing sample comprising use of fluorescent labels and hybridization chain reaction.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C12Q 1/6813 - Hybridisation assays
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/06 - Quantitative determination
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

Disclosed is a method for administering a transgene into a fibroblast in a subject comprising: a) providing a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein said recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide to be expressed in said fibroblast; and b) providing a pharmaceutically acceptable carrier, wherein said HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 35/763 - Herpes virus
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

This document provides AAV9 vectors. For example, AAV9 vectors containing an AAV9 capsid polypeptide that includes an amino acid sequence set forth in Table 1A (or a variant thereof) or Formula A or an amino acid sequence set forth in Table 1B (or a variant thereof) or Formula B are provided as are such AAV9 capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV9 capsid polypeptides, host cells containing and/or expressing such nucleic acid molecules, and methods and materials for making or using such vectors and/or AAV9 capsid polypeptides.

IPC Classes  ?

• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C12N 15/864 - Parvoviral vectors
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Provided are methods for preparing sterilized, gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth substrates. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.

IPC Classes  ?

• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/38 - Animal cells
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

The invention pertains to treating kidney disease and systems and methods for determining the rate of net fluid removal to be used during CKRT. According to the invention, determining the rate of net fluid removal includes calculating a predicted body weight of the patient based on patient's height, determining a net fluid removal rate from the patient in volume/mass/time based on the predicted body weight of the patient and a restrictive or a liberal strategy, calculating a total rate of continuous intravenous fluids infused into the patient in volume/mass/time, and adding the total rate of continuous intravenous fluids infused to the net fluid removal rate. The net fluid removal rate is used to set the continuous dialysis machine to remove a corresponding fluid volume from the patient during CKRT.

IPC Classes  ?

• A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

Abstract

The present disclosure relates to methods of treating patients having liver cancer by performing a genome-targeting technique. It is based, at least in part, on the discovery that a genome editing technique that specifically targets genomic mutations can induce cell death in a cancer cell, e.g., a hepatocellular cancer cell, having the genomic gene. The present disclosure provides methods for treating cancer patients that include performing a genome editing technique targeting a genomic mutation present within one or more cells of a subject to produce an anti-cancer effect.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 38/46 - Hydrolases (3)
• A61P 35/00 - Antineoplastic agents
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/52 - Genes encoding for enzymes or proenzymes

Abstract

ZTA/BZLF1ZTA/BZLF1ZTA/BZLF1 promoter.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 38/46 - Hydrolases (3)
• A61K 9/51 - Nanocapsules
• A61P 35/00 - Antineoplastic agents
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses

Abstract

This document relates to AAV vectors (e.g., AAV2 vectors). For example, AAV vectors (e.g., AAV2 vectors) containing an AAV capsid polypeptide that includes an amino acid sequence set forth in Table 1A (or a variant thereof) or Formula A, an amino acid sequence set forth in Table 1B (or a variant thereof) or Formula B, or an amino acid sequence set forth in Table 1C (or a variant thereof) or Formula C, such AAV capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV capsid polypeptides, host cells containing and/or expressing such nucleic acid molecules, and methods and materials for making or using such vectors and/or AAV capsid polypeptides are provided.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 27/02 - Ophthalmic agents
• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus

Abstract

Provided herein are compositions and methods for increasing an immune response in a subject, immunizing a subject and/or treating a disease in a subject that relate to keratinocytes. It is a surprising finding of the present invention that modulation of an XBP1 pathway creates a keratinocyte that is itself an immune modulator, or adjuvant. In some embodiments, the concentration of antigen is increased in the vicinity of the keratinocyte, further increasing the immune response by effector cells within that vicinity.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/02 - Bacterial antigens
• A61K 39/12 - Viral antigens
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

Neuroblastoma (NB) remains a leading cause of childhood cancer morbidity and mortality. Heritable activating mutations are present in the anaplastic lymphoma kinase (ALK) oncogene and these same mutations are frequently somatically acquired during high-risk NB tumorigenesis. ALK has been established as a tractable molecular target in NB and provides the rationale for the clinical development of ALK inhibition therapy. Anti-ALK antibodies and antigen binding fragments thereof are provided along with methods of use thereof.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents

Abstract

A fiber optic based sensing system and method includes a. functionalized optical fiber based sensor including an engineered sensing layer, a light source structured to generate light and couple the light into an input of the functionalized optical fiber based sensor, and an interrogator including a photodetector coupled to the functionalized optical fiber based sensor to receive transmitted or reflected tight, a transimpedance amplifier (TIA) circuit coupled to an output of the photodetector, a controller coupled to an output of the TIA circuit, and a transmitter (e.g., a wired or wireless transmitter) coupled to the controller.

IPC Classes  ?

• G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
• H03F 3/08 - Amplifiers with only discharge tubes or only semiconductor devices as amplifying elements with semiconductor devices only controlled by light
• H04B 10/67 - Optical arrangements in the receiver

Abstract

Provided herein are methods of making an ECM gel from vascular tissue. Also provided herein are ECM compositions prepared from vascular tissue, and methods of use of those compositions, for example in treatment of aneurysms, and for vascularization or re-vascularization.

IPC Classes  ?

• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 27/52 - Hydrogels or hydrocolloids
• C07K 14/745 - Blood coagulation or fibrinolysis factors
• C07K 14/75 - Fibrinogen

Abstract

The invention relates to dental bone grafting devices and magnesium meshes having features that are designed to corrode and/or absorb progressively, e.g., in stages, in order to improve dental bone regeneration, as well as methods for preparing the meshes. The meshes include a framework, and a geometric design is formed within the framework that includes design features. The geometric design and design features are selected and manipulated to provide the progressive corrosion and/or absorption profile of the mesh.

IPC Classes  ?

• A61C 8/02 - Means for transfixation of natural teeth
• A61L 27/04 - Metals or alloys
• A61L 27/58 - Materials at least partially resorbable by the body

Abstract

The invention relates to biodegradable iron alloy-containing compositions for use in preparing medical devices. In addition, biodegradable crystalline and amorphous compositions of the invention exhibit properties that make them suitable for use as medical devices for implantation into a body of a patient. The compositions include elemental iron, and one or more elements selected from manganese, magnesium, zirconium, zinc and calcium. The compositions can be prepared using a high energy milling technique. The resulting compositions and the devices formed therefrom are useful in various surgical procedures, such as but not limited to orthopedic, craniofacial, tracheal, and cardiovascular.

IPC Classes  ?

• A61L 31/02 - Inorganic materials
• A61L 31/14 - Materials characterised by their function or physical properties
• C22C 33/10 - Making cast-iron alloys including procedures for adding magnesium
• C22C 38/00 - Ferrous alloys, e.g. steel alloys
• C22C 38/04 - Ferrous alloys, e.g. steel alloys containing manganese
• C22C 38/14 - Ferrous alloys, e.g. steel alloys containing titanium or zirconium
• C22C 45/02 - Amorphous alloys with iron as the major constituent

Abstract

Methods are disclosed for generating a target mean arterial pressure (MAP) for a patient during a surgery. In some implementations, the disclosed methods include calculating the target MAP based on the age, biological sex, emergent surgery status, and American Society of Anesthesiology (ASA) physical status (PS) class of the patient, and a predetermined intraoperative hypotension (IOH) risk benchmark. Treating the patient to maintain a MAP at or above the target MAP during the surgery reduces a risk of IOH during the surgery, a risk of administering an unnecessary therapy to avoid IOH during the surgery; and a risk of not administering a therapeutic MAP-decreasing action during the surgery. In some implementations, the method further comprises conducting the surgery on the patient and treating the patient to maintain the MAP of the patient at or above the target MAP during the surgery. Also provided are systems for implementing the disclosed methods.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/021 - Measuring pressure in heart or blood vessels

Abstract

Disclosed are recombinant herpes simplex virus (HSV) vectors comprising an insulator sequence comprising at least 95% identity to at least one of SEQ ID NOs: 1-4, wherein the insulator sequence comprising at least 95% identity to at least one of SEQ ID NOs: 1-4 is positioned in an intergenic region, a LAT locus, or an ICP4 locus of the vector. Also described are pharmaceutical compositions comprising the vectors and methods of using the vectors.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 35/763 - Herpes virus
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Monoclonal antibodies and antigen binding fragments that specifically bind MCT11 are provided. Also disclosed are nucleic acid molecules encoding the antibody, vectors including these nucleic acid molecules, and host cells transfected with these vectors. Methods of using MCT11 specific antibodies to treat cancer, inhibit or treat T cell exhaustion, and/or enhance immunotherapy, are also provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Described here are ophthalmic compositions and methods for treatment of dry eye disease. One ophthalmic composition includes an effective amount of interleukin-4 (IL-4) in a free uncomplexed form, or as a complex with a dermatan sulfate. A second ophthalmic composition includes an effective amount of interleukin-13 (IL-13) in a free uncomplexed form, or as a complex with a dermatan sulfate. A third ophthalmic composition includes effective amounts of IL-4 and IL-13 in a free uncomplexed form, or as a complex with a dermatan sulfate. A fourth ophthalmic composition includes at least one activator of interleukin-4 receptor signaling in a free uncomplexed form, or as a complex with a dermatan sulfate.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/726 - Glycosaminoglycans, i.e. mucopolysaccharides
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 27/02 - Ophthalmic agents

Abstract

The present disclosure relates to methods, compositions, and kits for treating traumatic brain injury (TBI) and TBI-associated impairments in a subject. The methods include administering to the subject an interleukin-7 (IL-7) or IL-7 agonist, a tumor necrosis factor alpha (TNFα) inhibitor, or both. The present disclosure also relates to methods of using biomarkers for identifying a subject that is likely to respond to a treatment for TBI-associated impairments, and monitoring the subject's response to such treatment.

IPC Classes  ?

• A61K 38/20 - Interleukins
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A therapeutic system or combination includes a first therapeutic agent to treat a disease condition and a second therapeutic agent adnrinistrable within a predetermined time of administration of the first therapeutic agent the second therapeutic agent inhibiting the function of Xkr8.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent